Evaluation and cost assessment of fluoroquinolones in community-acquired respiratory infections

Author： Sahloff Eric G Close Sandy J Martin Steven J

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.3, Iss.9, 2002-09, pp. : 1251-1266

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

What is the Place of Fluoroquinolones in the Treatment of Community-Acquired Respiratory Tract Infections?

By Momméja-Marin H. Carbon C.

Drugs, Vol. 57, Iss. 6, 1999-06 ,pp. : 851-853

Adis International

Access to resources Recommend Favorite

Clarithromycin extended-release in community-acquired respiratory tract infections

By Williams Kathy N Bishai William R

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 16, 2005-12 ,pp. : 2867-2876

Informa Healthcare

Access to resources Recommend Favorite

Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections

By Hammerschlag Margaret R Sharma Roopali

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 3, 2008-03 ,pp. : 387-400

Informa Healthcare

Access to resources Recommend Favorite

Community-acquired infections - the role of gatifloxacin

Inpharma, Vol. 1, Iss. 1231, 2000-01 ,pp. : 11-12

Adis International

Access to resources Recommend Favorite

Emergence of community-acquired MRSA infections

Inpharma, Vol. 1, Iss. 1306, 2001-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite